- Open
- 680.00
- High
- 695.00
- Low
- 680.00
- Close
- 680.00
- Change
- -20.00 (-2.86%)
- Volume
- 5,519
⌘K
| 30 Apr 2026 | 16:04:40 | Final Results |
| 28 Apr 2026 | 07:00:06 | Institutional Fundraise |
| 14 Apr 2026 | 07:00:06 | Annual IND Report with FDA |
| 31 Mar 2026 | 13:22:00 | Tech Transfer Completion and Clinical Trial Update |
| 20 May 2025 | Annual Report & Financial Statements for the Year Ended 31 December 2024 | |
| 1 Jan 2025 | Official (PDF) | |
| 25 Apr 2024 | Annual Report & Financial Statements for the Year Ended 31 December 2023 |
Hemogenyx Pharmaceuticals is a biopharmaceutical company in the pre-clinical stage that is focused on developing innovative treatments for blood and autoimmune disorders. Their goal is to harness the healing potential of bone marrow transplantation to provide curative therapies.
| 30 Apr 2026 | 16:04:40 | Final Results |
| 28 Apr 2026 | 07:00:06 | Institutional Fundraise |
| 14 Apr 2026 | 07:00:06 | Annual IND Report with FDA |
| 31 Mar 2026 | 13:22:00 | Tech Transfer Completion and Clinical Trial Update |
| 20 May 2025 | Annual Report & Financial Statements for the Year Ended 31 December 2024 | |
| 1 Jan 2025 | Official (PDF) | |
| 25 Apr 2024 | Annual Report & Financial Statements for the Year Ended 31 December 2023 |
Hemogenyx Pharmaceuticals is a biopharmaceutical company in the pre-clinical stage that is focused on developing innovative treatments for blood and autoimmune disorders. Their goal is to harness the healing potential of bone marrow transplantation to provide curative therapies.
| 27 Feb 2026 |
| 08:10:00 |
| Total Voting Rights |
| 27 Feb 2026 |
| 08:10:00 |
| Total Voting Rights |
